Next Article in Journal
A Mixed-Methods Cohort Study to Determine Perceived Patient Benefit in Providing Custom Breast Prostheses
Previous Article in Journal
A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 2
10.3747/co.19.1024
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy

by
J.P.M. Ayoub
1,
Sh. Verma
2,* and
Su. Verma
3
1
Hematology–Oncology Service, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canda
2
Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canda
3
Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canda
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(2), 91-105; https://doi.org/10.3747/co.19.1024
Submission received: 6 March 2012 / Revised: 8 March 2012 / Accepted: 13 March 2012 / Published: 1 April 2012

Abstract

This article provides an overview of recent advances in chemotherapy that may be used for the treatment of patients with locally advanced or metastatic breast cancer (mbc). Key phase ii and iii trial data for eribulin mesylate, ixabepilone, and nab-paclitaxel, published since 2006, are discussed on the basis of recency, depth, and quality. Eribulin mesylate is the first monotherapy to significantly increase overall survival in patients with pretreated mbc, but nab-paclitaxel offers a novel and safer mode of delivery in comparison with standard taxanes. By contrast, the use of ixabepilone will be limited for now, until the associated neurotoxicity can be better managed. Alongside a brief overview of the other major chemotherapies currently in use, we have aimed to provide a Canadian context for how these novel agents may be integrated into clinical practice.
Keywords: pretreated; breast cancer; metastatic; mbc; chemotherapy; eribulin; ixabepilone; nab-paclitaxel pretreated; breast cancer; metastatic; mbc; chemotherapy; eribulin; ixabepilone; nab-paclitaxel

Share and Cite

MDPI and ACS Style

Ayoub, J.P.M.; Verma, S.; Verma, S. Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy. Curr. Oncol. 2012, 19, 91-105. https://doi.org/10.3747/co.19.1024

AMA Style

Ayoub JPM, Verma S, Verma S. Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy. Current Oncology. 2012; 19(2):91-105. https://doi.org/10.3747/co.19.1024

Chicago/Turabian Style

Ayoub, J.P.M., Sh. Verma, and Su. Verma. 2012. "Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy" Current Oncology 19, no. 2: 91-105. https://doi.org/10.3747/co.19.1024

APA Style

Ayoub, J. P. M., Verma, S., & Verma, S. (2012). Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy. Current Oncology, 19(2), 91-105. https://doi.org/10.3747/co.19.1024

Article Metrics

Back to TopTop